186 related articles for article (PubMed ID: 38341510)
1. Tumorigenic role of tacrolimus through mTORC1/C2 activation in post-transplant renal cell carcinomas.
Moldvai D; Sztankovics D; Dankó T; Vetlényi E; Petővári G; Márk Á; Patonai A; Végső G; Piros L; Hosszú Á; Pápay J; Krencz I; Sebestyén A
Br J Cancer; 2024 Apr; 130(7):1119-1130. PubMed ID: 38341510
[TBL] [Abstract][Full Text] [Related]
2. Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.
Kauffman EC; Lang M; Rais-Bahrami S; Gupta GN; Wei D; Yang Y; Sourbier C; Srinivasan R
BMC Cancer; 2019 Sep; 19(1):917. PubMed ID: 31519159
[TBL] [Abstract][Full Text] [Related]
3. Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospective study with RCC diagnosed in the general population.
Breda A; Lucarelli G; Rodriguez-Faba O; Guirado L; Facundo C; Bettocchi C; Gesualdo L; Castellano G; Grandaliano G; Battaglia M; Palou J; Ditonno P; Villavicencio H
World J Urol; 2015 Jan; 33(1):1-7. PubMed ID: 24504760
[TBL] [Abstract][Full Text] [Related]
4. Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities?
Gigante M; Neuzillet Y; Patard JJ; Tillou X; Thuret R; Branchereau J; Timsit MO; Terrier N; Boutin JM; Sallusto F; Karam G; Barrou B; Chevallier D; Mazzola CR; Delaporte V; Doeffler A; Kleinclauss F; Badet L; ;
BJU Int; 2012 Dec; 110(11 Pt B):E570-3. PubMed ID: 22726451
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus trough levels higher than 6 ng/mL might not be required after a year in stable kidney transplant recipients.
Jung HY; Seo MY; Jeon Y; Huh KH; Park JB; Jung CW; Lee S; Han SY; Ro H; Yang J; Ahn C; Choi JY; Cho JH; Park SH; Kim YL; Kim CD
PLoS One; 2020; 15(7):e0235418. PubMed ID: 32614859
[TBL] [Abstract][Full Text] [Related]
6. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens.
Felix MJ; Felipe CR; Tedesco-Silva H; Osmar Medina-Pestana J
Pharmacotherapy; 2016 Feb; 36(2):152-65. PubMed ID: 26799522
[TBL] [Abstract][Full Text] [Related]
7. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the mTOR pathway: A new mechanism of β cell toxicity induced by tacrolimus.
Rodriguez-Rodriguez AE; Donate-Correa J; Rovira J; Cuesto G; Luis-Ravelo D; Fernandes MX; Acevedo-Arozena A; Diekmann F; Acebes A; Torres A; Porrini E
Am J Transplant; 2019 Dec; 19(12):3240-3249. PubMed ID: 31152486
[TBL] [Abstract][Full Text] [Related]
9. Effects of resveratrol on Th17 cell-related immune responses under tacrolimus-based immunosuppression.
Doh KC; Kim BM; Kim KW; Chung BH; Yang CW
BMC Complement Altern Med; 2019 Mar; 19(1):54. PubMed ID: 30832648
[TBL] [Abstract][Full Text] [Related]
10. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia.
Tickoo SK; dePeralta-Venturina MN; Harik LR; Worcester HD; Salama ME; Young AN; Moch H; Amin MB
Am J Surg Pathol; 2006 Feb; 30(2):141-53. PubMed ID: 16434887
[TBL] [Abstract][Full Text] [Related]
11. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
[TBL] [Abstract][Full Text] [Related]
12. Preclinical trial of a new dual mTOR inhibitor, MLN0128, using renal cell carcinoma tumorgrafts.
Ingels A; Zhao H; Thong AE; Saar M; Valta MP; Nolley R; Santos J; Peehl DM
Int J Cancer; 2014 May; 134(10):2322-9. PubMed ID: 24243565
[TBL] [Abstract][Full Text] [Related]
13. Conversion from tacrolimus-mycophenolate mofetil to tacrolimus-mTOR immunosuppression after kidney-pancreas transplantation reduces the incidence of both BK and CMV viremia.
Knight RJ; Graviss EA; Nguyen DT; Kuten SA; Patel SJ; Gaber L; Gaber AO
Clin Transplant; 2018 Jun; 32(6):e13265. PubMed ID: 29676018
[TBL] [Abstract][Full Text] [Related]
14. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
15. Renal tumours in a Tsc2(+/-) mouse model do not show feedback inhibition of Akt and are effectively prevented by rapamycin.
Yang J; Kalogerou M; Samsel PA; Zhang Y; Griffiths DF; Gallacher J; Sampson JR; Shen MH
Oncogene; 2015 Feb; 34(7):922-31. PubMed ID: 24632604
[TBL] [Abstract][Full Text] [Related]
16. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
17. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-214 Reduces Insulin-like Growth Factor-1 (IGF-1) Receptor Expression and Downstream mTORC1 Signaling in Renal Carcinoma Cells.
Das F; Dey N; Bera A; Kasinath BS; Ghosh-Choudhury N; Choudhury GG
J Biol Chem; 2016 Jul; 291(28):14662-76. PubMed ID: 27226530
[TBL] [Abstract][Full Text] [Related]
19. Suppressive Effect of 1α,25-Dihydroxyvitamin D3 on Th17-Immune Responses in Kidney Transplant Recipients With Tacrolimus-Based Immunosuppression.
Chung BH; Kim BM; Doh KC; Min JW; Cho ML; Kim KW; Yang CW
Transplantation; 2017 Jul; 101(7):1711-1719. PubMed ID: 28107277
[TBL] [Abstract][Full Text] [Related]
20. Pre-clinical evaluation of AZD-2014, a novel mTORC1/2 dual inhibitor, against renal cell carcinoma.
Zheng B; Mao JH; Qian L; Zhu H; Gu DH; Pan XD; Yi F; Ji DM
Cancer Lett; 2015 Feb; 357(2):468-75. PubMed ID: 25444920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
